Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Daiichi Sankyo
Chubb
Fish and Richardson
Argus Health
Mallinckrodt
Citi
Chinese Patent Office
Dow

Generated: June 24, 2018

DrugPatentWatch Database Preview

MYLAXEN Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Mylaxen, and when can generic versions of Mylaxen launch?

Mylaxen is a drug marketed by Medpointe Pharm Hlc and is included in one NDA.

The generic ingredient in MYLAXEN is hexafluorenium bromide. There is one drug master file entry for this compound. Additional details are available on the hexafluorenium bromide profile page.
Summary for MYLAXEN
Drug patent expirations by year for MYLAXEN
Synonyms for MYLAXEN
1,6-Bis(9 fluorenyldimethyl-ammonium)hexane bromide
1,6-Hexanediaminium, N,N'-di-9H-fluoren-9-yl-N,N,N',N'-tetramethyl-, dibromide
317-52-2
3B1-004273
4844-10-4 (Parent)
9H-fluoren-9-yl-[6-[9H-fluoren-9-yl(dimethyl)azaniumyl]hexyl]-dimethylazanium dibromide
AC1L1T17
AKOS030228688
Ammonium, hexamethylenebis(fluoren-9-yldimethyl-, bromide
AMMONIUM, HEXAMETHYLENEBIS(FLUOREN-9-YLDIMETHYL-, DIBROMIDE
B64NJG83K2
BDBM50016845
Bromure d'hexafluronium
Bromure d'hexafluronium [INN-French]
Bromuro de hexafluronio
Bromuro de hexafluronio [INN-Spanish]
C36H42N2
CAS-317-52-2
CHEMBL1200933
D04435
D0Q2MH
DSSTox_CID_28679
DSSTox_GSID_48753
DSSTox_RID_82949
DTXSID6048753
EINECS 206-265-0
Esafluronio bromuro
Esafluronio bromuro [DCIT]
hexafluorenium
Hexafluorenium bromide
Hexafluorenium bromide (USAN)
Hexafluorenium bromide [USAN]
Hexafluorenium dibromide
hexafluorenium dibromide salt
HEXAFLURONE BROMIDE
Hexafluronii bromidum
Hexafluronii bromidum [INN-Latin]
Hexafluronium bromide
Hexafluronium bromide (INN)
hexafluroniumbromide
Hexamethylene bis(9-fluorenyldimethylammonium)dibromide
Hexamethylenebis(9-fluorenyldimethylammonium bromide)
Hexamethylenebis(dimethyl-9-fluorenylammonium bromide)
Hexamethylenebis(fluoren-9-yldimethylammonium) dibromide
IN-117
KS-00000118
LP085070
LS-18141
Milaxen
MolPort-006-111-202
Mylaxen (TN)
N-[6-(9H-fluoren-9-yldimethylaminio)hexyl]-N,N-dimethyl-9H-fluoren-9-aminium dibromide
N-[6-(9H-FLUOREN-9-YLDIMETHYLAMMONIO)HEXYL]-N,N-DIMETHYL-9H-FLUOREN-9-AMINIUM DIBROMIDE
N-{6-[(9H-fluoren-9-yl)dimethylazaniumyl]hexyl}-N,N-dimethyl-9H-fluoren-9-aminium dibromide
N,N'-Di(9-fluorenyl)-N,N,N',N'-tetramethyly-hexamethylendi(ammoniumbromid)
NCGC00182971-01
NSC-19477
PL011299
SCHEMBL120924
Tox21_113214
UNII-B64NJG83K2

US Patents and Regulatory Information for MYLAXEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medpointe Pharm Hlc MYLAXEN hexafluorenium bromide INJECTABLE;INJECTION 009789-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Federal Trade Commission
Teva
Cipla
Chubb
Citi
McKesson
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.